Literature DB >> 21138859

Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion.

Jian-Jun Wei1, Xinyu Wu, Yi Peng, Guizhi Shi, Olca Basturk, Basturk Olca, Ximing Yang, Garrett Daniels, Iman Osman, Jiangyong Ouyang, Eva Hernando, Angel Pellicer, Johng S Rhim, Jonathan Melamed, Peng Lee.   

Abstract

PURPOSE: High-motility group AT-hook gene 1 (HMGA1) is a non-histone nuclear binding protein that is developmentally regulated. HMGA1 is significantly overexpressed in and associated with high grade and advance stage of prostate cancer (PC). The oncogenic role of HMGA1 is at least mediated through chromosomal instability and structural aberrations. However, regulation of HMGA1 expression is not well understood. Identification of microRNA-mediated HMGA1 regulation will provide a promising therapeutic target in treating PC. EXPERIMENTAL
DESIGN: In this study, we examined the functional relation between miR-296 and HMGA1 expression in several PC cell lines and a large PC cohort. We further examined the oncogenic property of HMGA1 regulated by miR-296.
RESULTS: Here we report that miR-296, a microRNA predicted to target HMGA1, specifically represses HMGA1 expression by promoting degradation and inhibiting HMGA1translation. Repression of HMGA1 by miR-296 is direct and sequence specific. Importantly, ectopic miR-296 expression significantly reduced PC cell proliferation and invasion, in part through the downregulation of HMGA1. Examining PC patient samples, we found an inverse correlation between HMGA1 and miR-296 expression: high levels of HMGA1 were associated with low miR-296 expression and strongly linked to more advanced tumor grade and stage.
CONCLUSIONS: Our results indicate that miR-296 regulates HMGA1 expression and is associated with PC growth and invasion. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138859      PMCID: PMC3196617          DOI: 10.1158/1078-0432.CCR-10-0993

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  Regulation of HMGIC expression: an architectural transcription factor involved in growth control and development.

Authors:  T A Ayoubi; E Jansen; S M Meulemans; W J Van de Ven
Journal:  Oncogene       Date:  1999-09-09       Impact factor: 9.867

2.  Substrate requirements for let-7 function in the developing zebrafish embryo.

Authors:  Wigard P Kloosterman; Erno Wienholds; René F Ketting; Ronald H A Plasterk
Journal:  Nucleic Acids Res       Date:  2004-12-07       Impact factor: 16.971

3.  High level expression of the HMGI (Y) gene during embryonic development.

Authors:  G Chiappetta; V Avantaggiato; R Visconti; M Fedele; S Battista; F Trapasso; B M Merciai; V Fidanza; V Giancotti; M Santoro; A Simeone; A Fusco
Journal:  Oncogene       Date:  1996-12-05       Impact factor: 9.867

4.  Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y).

Authors:  K R Johnson; D A Lehn; T S Elton; P J Barr; R Reeves
Journal:  J Biol Chem       Date:  1988-12-05       Impact factor: 5.157

Review 5.  MicroRNAs and chromosomal abnormalities in cancer cells.

Authors:  G A Calin; C M Croce
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

6.  High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells.

Authors:  Natsuki Takaha; Anita L Hawkins; Constance A Griffin; William B Isaacs; Donald S Coffey
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

7.  Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.

Authors:  Y Tamimi; H G van der Poel; M M Denyn; R Umbas; H F Karthaus; F M Debruyne; J A Schalken
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

9.  Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.

Authors:  Long G Wang; Liliana Ossowski; Anna C Ferrari
Journal:  Oncogene       Date:  2004-07-01       Impact factor: 9.867

10.  A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.

Authors:  Y Tamimi; H G van der Poel; H F Karthaus; F M Debruyne; J A Schalken
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more
  42 in total

Review 1.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

2.  A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma.

Authors:  Huan Chen; Xiangzhen Liu; Zhenning Jin; Chenyu Gou; Minglu Liang; Li Cui; Xinyuan Zhao
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  Oxidative stress-induced miRNAs modulate AKT signaling and promote cellular senescence in uterine leiomyoma.

Authors:  Xiuhua Xu; J Julie Kim; Yinuo Li; Jia Xie; Changshun Shao; Jian-Jun Wei
Journal:  J Mol Med (Berl)       Date:  2018-08-10       Impact factor: 4.599

4.  Silencing of HMGA1 expression by RNA interference suppresses growth of osteogenic sarcoma.

Authors:  Shaohui Yuan; Qi Pan; Chunjiang Fu; Zhenggang Bi
Journal:  Mol Cell Biochem       Date:  2011-05-15       Impact factor: 3.396

5.  Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.

Authors:  Charles Chuanhai Guo; Vipulkumar Dadhania; Li Zhang; Tadeusz Majewski; Jolanta Bondaruk; Maciej Sykulski; Weronika Wronowska; Anna Gambin; Yan Wang; Shizhen Zhang; Enrique Fuentes-Mattei; Ashish Madhav Kamat; Colin Dinney; Arlene Siefker-Radtke; Woonyoung Choi; Keith A Baggerly; David McConkey; John N Weinstein; Bogdan Czerniak
Journal:  Eur Urol       Date:  2016-03-15       Impact factor: 20.096

6.  MicroRNAs 296 and 298 are imprinted and part of the GNAS/Gnas cluster and miR-296 targets IKBKE and Tmed9.

Authors:  Joan E Robson; Sally A Eaton; Peter Underhill; Debbie Williams; Jo Peters
Journal:  RNA       Date:  2011-11-23       Impact factor: 4.942

7.  High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells.

Authors:  Yunzhi Zhang; Teng Ma; Shuping Yang; Mingying Xia; Jing Xu; Haijia An; Yajun Yang; Shilin Li
Journal:  Mol Cell Biochem       Date:  2011-06-09       Impact factor: 3.396

Review 8.  MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.

Authors:  J Jones; W Grizzle; H Wang; C Yates
Journal:  Biotech Histochem       Date:  2013-08-01       Impact factor: 1.718

9.  miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.

Authors:  Zhaojian Liu; Elizabeth Gersbach; Xiyu Zhang; Xiaofei Xu; Ruifen Dong; Peng Lee; Jinsong Liu; Beihua Kong; Changshun Shao; Jian-Jun Wei
Journal:  Mol Cancer Res       Date:  2013-09-17       Impact factor: 5.852

10.  Regulation of lung cancer metastasis by Klf4-Numb-like signaling.

Authors:  Valentina Vaira; Alice Faversani; Nina M Martin; David S Garlick; Stefano Ferrero; Mario Nosotti; Joseph L Kissil; Silvano Bosari; Dario C Altieri
Journal:  Cancer Res       Date:  2013-02-25       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.